The Prognostic Value of Biomarkers on Detecting Non-Small Cell Lung Cancer in a Chinese Elderly Population

References

• Xue C, Hu Z, Jiang W, et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer. 2012;77(2):371–375. doi:10.1016/j.lungcan.2012.04.014
   PubMed Web of Science ®Google Scholar
• Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27. doi:10.1158/1055-9965.EPI-15-0578
   PubMed Web of Science ®Google Scholar
• Kulpa J, Wójcik E, Reinfuss M, Kołodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem. 2002;48(11):1931–1937. doi:10.1093/clinchem/48.11.1931
   PubMed Web of Science ®Google Scholar
• Diamandis EP, Hoffman BR, Sturgeon CM. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines for the use of tumor markers. Clin Chem. 2008;54(11):1935–1939. doi:10.1373/clinchem.2008.105494
   PubMed Web of Science ®Google Scholar
• Wang X, Fan Y, Wang J, Wang H, Liu W. Evaluating the expression and diagnostic value of human epididymis protein 4 (HE4) in small cell lung cancer. Tumour Biol. 2014;35(7):6847–6853. doi:10.1007/s13277-014-1943-8
   PubMedGoogle Scholar
• Speeckaert MM, Speeckaert R, Delanghe JR. Human epididymis protein 4 in cancer diagnostics: a promising and reliable tumor marker. Adv Clin Chem. 2013;59:1–21.
   PubMed Web of Science ®Google Scholar
• Scaletta G, Plotti F, Luvero D, et al. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review. Expert Rev Anticancer Ther. 2017;17(9):827–839. doi:10.1080/14737140.2017.1360138
   PubMed Web of Science ®Google Scholar
• Lu KH, Patterson AP, Wang L, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004;10(10):3291–3300. doi:10.1158/1078-0432.CCR-03-0409
   PubMed Web of Science ®Google Scholar
• Lawton AJ, Lee KA, Cheville AL, et al. Assessment and management of patients with metastatic spinal cord compression: a multidisciplinary review. J Clin Oncol. 2019;37(1):61–71. doi:10.1200/JCO.2018.78.1211
   PubMed Web of Science ®Google Scholar
• Karlsen NS, Karlsen MA, Høgdall CK, Høgdall EV. HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2285–2295. doi:10.1158/1055-9965.EPI-14-0447
   PubMed Web of Science ®Google Scholar
• Kristjansdottir B, Levan K, Partheen K, Sundfeldt K. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. Gynecol Oncol. 2013;131(1):52–58. doi:10.1016/j.ygyno.2013.07.094
   PubMed Web of Science ®Google Scholar
• Kamei M, Yamashita S, Tokuishi K, et al. HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer. Anticancer Res. 2010;30(11):4779–4783.
   PubMed Web of Science ®Google Scholar
• Lan WG, Hao YZ, Xu DH, Wang P, Zhou YL, Ma LB. Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer. Clin Transl Oncol. 2016;18(4):375–380. doi:10.1007/s12094-015-1375-y
   PubMed Web of Science ®Google Scholar
• Lamy PJ, Plassot C, Pujol JL, de Mello RA. Serum HE4: an independent prognostic factor in non-small cell lung cancer. PLoS One. 2015;10(6):e0128836. doi:10.1371/journal.pone.0128836
   PubMed Web of Science ®Google Scholar
• Jiang Y, Wang C, Lv B, Ma G, Wang L. Expression level of serum human epididymis 4 and its prognostic significance in human non-small cell lung cancer. Int J Clin Exp Med. 2014;7(12):5568–5572.
   PubMed Web of Science ®Google Scholar
• Liu W, Yang J, Chi PD, et al. Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis. Int J Tuberc Lung Dis. 2013;17(10):1346–1353. doi:10.5588/ijtld.13.0058
   PubMed Web of Science ®Google Scholar
• Yamashita S, Tokuishi K, Hashimoto T, et al. Prognostic significance of HE4 expression in pulmonary adenocarcinoma. Tumour Biol. 2011;32(2):265–271. doi:10.1007/s13277-010-0118-5
   PubMed Web of Science ®Google Scholar
• Lou E, Johnson M, Sima C, et al. Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer. Cancer Biomark. 2014;14(4):207–214. doi:10.3233/CBM-140399
   PubMed Web of Science ®Google Scholar
• Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–1640. doi:10.1016/j.mayocp.2019.01.013
   PubMed Web of Science ®Google Scholar
• Stevens PE. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825. doi:10.7326/0003-4819-158-11-201306040-00007
   PubMed Web of Science ®Google Scholar
• Potenza E, Parpinel G, Laudani ME, Macchi C, Fuso L, Zola P. Prognostic and predictive value of combined HE-4 and CA-125 biomarkers during chemotherapy in patients with epithelial ovarian cancer. Int J Biol Markers. 2020;35(4):20–27. doi:10.1177/1724600820955195
   PubMed Web of Science ®Google Scholar
• Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem. 2011;57(11):1534–1544. doi:10.1373/clinchem.2010.157073
   PubMed Web of Science ®Google Scholar
• Mo D, He F. Serum human epididymis secretory protein 4 (HE4) is a potential prognostic biomarker in non-small cell lung cancer. Clin Lab. 2018;64(4):1421–1428. doi:10.7754/Clin.Lab.2018.180222
   PubMed Web of Science ®Google Scholar
• Li LM, Zhu YX, Zhong Y, et al. Human epididymis protein 4 in endometrial cancer: a meta-analysis. Clin Chim Acta. 2018;482:215–223. doi:10.1016/j.cca.2018.03.040
   PubMed Web of Science ®Google Scholar
• LeBleu VS, Teng Y, O’Connell JT, et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med. 2013;19(2):227–231. doi:10.1038/nm.2989
   PubMed Web of Science ®Google Scholar
• Luo J, Wang F, Wan J, et al. Serum human epididymis secretory protein 4 as a potential biomarker of renal fibrosis in kidney transplantation recipients. Clin Chim Acta. 2018;483:216–221. doi:10.1016/j.cca.2018.05.006
   PubMed Web of Science ®Google Scholar
• Yuan T, Li Y. Human epididymis protein 4 as a potential biomarker of chronic kidney disease in female patients with normal ovarian function. Lab Med. 2017;48(3):238–243. doi:10.1093/labmed/lmx036
   PubMed Web of Science ®Google Scholar
• Tajima S, Fu R, Shigematsu T, et al. Urinary human epididymis secretory protein 4 as a useful biomarker for subclinical acute rejection three months after kidney transplantation. Int J Mol Sci. 2019;20(19):4699. doi:10.3390/ijms20194699
   PubMed Web of Science ®Google Scholar
• Piek A, Meijers WC, Schroten NF, Gansevoort RT, de Boer RA, Silljé HH. HE4 serum levels are associated with heart failure severity in patients with chronic heart failure. J Card Fail. 2017;23(1):12–19. doi:10.1016/j.cardfail.2016.05.002
   PubMed Web of Science ®Google Scholar
• Huang Y, Jiang H, Zhu L. Human epididymis protein 4 as an indicator of acute heart failure in patients with chronic kidney disease. Lab Med. 2020;51(2):169–175.
   PubMed Web of Science ®Google Scholar
• de Boer RA, Cao Q, Postmus D, et al. The WAP four-disulfide core domain protein HE4: a novel biomarker for heart failure. JACC Heart Fail. 2013;1(2):164–169. doi:10.1016/j.jchf.2012.11.005
   PubMed Web of Science ®Google Scholar